Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 17/20 | 0.74 |
| ▸ | KCNJ1 | P48048 | 16/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15196930 | 0.93 | KCNH2 (0.74) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL10286958 | 0.89 | KCNJ1 (0.74) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL4549659 | 0.89 | KCNH2 (0.74) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL4549567 | 0.88 | KCNJ1 (0.71) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL4549570 | 0.88 | KCNH2 (0.74) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL2731848 | 0.87 | KCNJ1 (0.70) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL16682207 | 0.85 | KCNJ1 (0.70) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL4549569 | 0.85 | KCNJ1 (0.65) | KCNH2KCNJ1 | |
| SCHEMBL2733634 | 0.85 | KCNH2 (1.00) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL4549574 | 0.85 | KCNH2 (1.00) | KCNH2KCNJ1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KCNH2 14/4885KCNJ1 2/4885SLC6A4 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.